Teaching Old Drugs New Tricks: The Promise and Pitfalls of Drug Repurposing
Presented by New England Healthcare Executive Network
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210-2600
The application of existing therapeutics to new disease indications holds enormous promise. Repurposed (sometimes call repositioned) drugs can be brought to market and have clinical impact faster and at much lower cost than de novo drug discovery. Commercializing an existing drug nevertheless presents challenges, even more so when the drug is a biologic. These span patent protection, regulatory and reimbursement treatment, off label competition from the existing generic, venture capital willingness to fund, and of course exit valuation.
Steven Corsello, MD, Postdoctoral Fellow, Broad Institute
Dr. Corsello is the founder of the Drug Repurposing Hub at the Broad Institute and an attending physician at the Dana-Farber Cancer Institute. He currently leads an effort to evaluate all available clinical drugs using information-rich cellular assays to develop new cancer treatments.
Jules Fried, CEO, Vasogenesis LLC
Jules is a serial entrepreneur, co-founder, and Chief Executive Officer of Vasogenesis LLC, a clinical stage drug company repurposing an off-patent biologic to treat vascular disease.
John Edwards, CEO and Founder, Drusolv Therapeutics Inc.
Drusolv Therapeutics, a clinical stage drug company that is repurposing statins for early intervention in age-related macular degeneration, in partnership with Massachusetts Eye and Ear.
Alexander “Zan” Fleming, MD, Founder and Executive Chairman, Kinexum LLC
Kinexum is a translational research consulting firm founded to support, accelerate, and advance efficient healthcare product innovation.
Janine Ladislaw, PhD, Registered Patent Attorney, Foley Hoag LLP
Janine’s practice focuses on strategic IP counseling, including patent procurement and monetization for emerging companies, public corporations, universities, and independent research institutions.
Alex Zisson, Managing Director, HIG Biotech Partners
At HIG, Alex focuses on investments in the biopharmaceuticals industry especially in pharmaceuticals, generics, drug delivery, and specialty pharma and biotechnology.
Join this timely program to hear about a unique drug development resource created by the Broad Institute and panelists experienced with the issues involved with bringing an off patent drug to market for a new use.
What to Expect
Our keynote speaker will describe the development and experience of the Drug Repurposing Hub while panelists comment upon the following topics associated with repurposing:
- Expenses avoided by repurposing
- Patent considerations
- Attitude of investors and strategic partners
- Regulatory pathways
Who should attend
C-level executives, board members, healthcare providers, venture capital and private equity investors, and anyone who wants a better understanding of opportunities and pitfalls of repurposing off patent drugs.
Click here for more details.